Apixaban (BMS-562247-01) is a compound being investigated as an anticoagulant.
Apixaban molecule is developed in a joint venture by Pfizer and Bristol-Myers Squibb …

Introduction Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the …

Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …

Eliquis™(apixaban) is the culmination of an intense medicinal chemistry effort to identify a
highly optimized inhibitor of coagulation factor Xa (FXa). We sought to identify a safe and …

An ability to readily determine an anticoagulant effect with an emerging class of direct, active
site, oral factor Xa inhibitors is viewed by the medical community as attractive and by some …

Background: Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late‐
stage clinical development for the prevention and treatment of thromboembolic diseases …

Conventional anticoagulant therapies can significantly reduce the risk of stroke and related
complications in patients with atrial fibrillation (AF). Classic oral anticoagulants based on …

Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Atrial fibrillation (AF) is a common cardiac arrhythmia, especially in the elderly population. It
is associated with cardioembolic complications, particularly strokes, resulting in severe …

Background: Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …